

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

**The effect of a milk lipid fraction on bone properties of
growing female rats and the growth and function of bone
cells**

A thesis presented in partial fulfilment of the requirements for

the degree of

Master of Science

in

Human Nutrition

at Massey University, Manawatu, Palmerston North,

New Zealand

Zhongling Cao

2014

MASSEY UNIVERSITY
APPLICATION FOR APPROVAL OF REQUEST TO EMBARGO A THESIS
(Pursuant to AC 98/168 (Revised 2), Approved by Academic Board 16.02.99)

This form is to be used when requesting a Thesis embargo. Once this form has been completed and signed by the Chief Supervisor it needs to be submitted to Wendy Dixon, Administration Manager, Graduate Research School, PN 713, to process for approval.

Name of Candidate: Zhongling Cao ID Number: 09211829

Degree: MSc Human Nutrition Dept/Institute/School: IFNHH

Thesis Title: The effect of a milk lipid fraction on bone cell proliferation and bone mineralisation in the growing rat.

Name of Chief Supervisor: Marlena Kruger Telephone 84571

As author of the above named thesis, I request that my thesis be embargoed from public access

until (date) April 2016 for the following reasons:

- Thesis contains commercially sensitive information.
- Thesis contains information which is personal or private and/or which was given on the basis that it not be disclosed.
- Immediate disclosure of thesis contents would not allow the author a reasonable opportunity to publish all or part of the thesis.
- Other (specify): _____

Please explain here why you think this request is justified:

The study was funded by Fonterra Brands Singapore Ltd and involves testing of a novel ingredient. This ingredient may be, if active, part of a new innovation for their flagship brand "Anlene". The master's study was a sub-study under the umbrella of a larger longer term rat feeding study, and the decision around IP cannot be made before the larger study is completed and the report written. The report is only due end of April which is after the submission date for the Master's thesis.

We will therefore also request the confidentiality agreements be signed by the examiners.

Signed (Candidate): [Signature] Date: 05.02.2014

Endorsed (Chief Supervisor): [Signature] Date: 5/2/14

Approved/Not Approved (Representative of VC): [Signature] 14/02/2014

Note: Copies of this form, once approved by the representative of the Vice-Chancellor, must be bound into every copy of the thesis.

Abstract

Objective: To investigate the effects of a milk lipid fraction (MLF) on the accrual of bone mass in growing rats by evaluating the effects of MLF on growth and bone parameters such as bone mineral content (BMC), bone mineral density (BMD) and biomechanical properties in growing rats and the effects of MLF on the development and activity of bone cells, including osteoblasts and osteoclasts.

Methods: There were one hundred and eight 3-month old female Sprague-Dawley rats were randomly allocated into three groups: a control group (n=48), a low-dose MLF group (n=30) fed with 250 mg/rat/day of MLF, and a high-dose MLF group (n=30) fed with 500 mg/rat/day of MLF. Forty-five rats (n=15 for each group) were selected to terminate at month 3 for biomechanical testing while sixty-three continued into a second arm of the trial after ovariectomy. Body composition and bone parameters of animals (n=108) were measured *in vivo* by Dual Energy X-Ray Absorptiometry (DEXA) at baseline and week 12 of the study. Length and diaphyseal width and thickness of the left femur were measured. The three-point bending test was used to evaluate the biomechanical characteristics of the left femur of rat. The effect of MLF on proliferation, differentiation and mineralization of murine osteoblasts were investigated using the osteoblastic cell line MC3T3-E1. The cells were cultured with 0-1,000 µg/ml or 0-100 µg/ml MLF for 5, 9 and 24 days, respectively for proliferation, differentiation and mineralization. Cell proliferation was determined using the methyl-thiazolyl tetrazolium (MTT) assay. The differentiation of osteoblasts was detected using the alkaline phosphatase (ALP) activity assay. Mineralized nodules were examined using an Alizarin red histochemistry assay. The effect of MLF on RANKL-induced osteoclastogenesis was evaluated in the murine monocytic cell line RAW264.7. The cells were cultured with 0-100 µg/ml MLF for five days. Osteoclastogenesis was determined using the tartrate-resistant acid phosphatase (TRAP) staining assay and counting numbers of TRAP-positive multinucleated cells.

Results: Rats fed with the high-dose MLF diet had a significant increase in body lean mass compared with those fed with the control and low-dose MLF diets. The high-dose MLF group also had significant gains in BMC at the femur and in BMD at

the femur and lumbar spine compared with the control group. There were no significant differences in dimensional and biomechanical results among groups. The MLF significantly increased the proliferation of MC3T3-E1 at 0.1, 1.0 and 100 µg/ml. There was a dose-dependent, but not significant increase in the differentiation of osteoblasts cultured with MLF for 9 days. After 24-days of cell culture, the MLF at the low concentrations of 0.1 and 1.0 µg/ml led to non-significant increase in calcium deposition by the differentiated osteoblasts. MLF at 10 and 100 µg/ml significantly inhibited calcium nodule formation. RANKL-stimulated osteoclastogenesis was significantly increased in RAW 264.7 cells cultured with the MLF at concentrations up to 10 µg/ml.

Conclusion: These results indicated that oral administration of MLF to the growing rats improved bone accrual and has a favourable effect on achievement of peak bone mass. The MLF increased the proliferation of MC3T3-E1 pre-osteoblast cell line, but there was no effect on osteoblast differentiation and the higher concentration of MLF may have inhibited the function of mature osteoblast. Additionally, the MLF stimulated osteoclastogenesis from RAW264.7 cells. Further studies are required to investigate some of the contradictory findings presented in this report.

Acknowledgements

The study reported in this thesis was conducted at Massey University in Palmerston North during April 2013 – April 2014, under the co-supervision of Professor Marlena Kruger and Dr Wei-Hang Chua.

I would like to first express my sincere gratitude to Professor Marlena Kruger and Dr Wei-Hang Chua for giving me the opportunity to be in this project. It could not have happened without you. I would also like to extend my appreciation and respect to you for your insights, knowledge and endless support, guidance, understanding and patience during my study. Thank you for helping me and encouraging me to my first step into science.

Thanks to Fonterra Brands Singapore Ltd for providing funding and the sample for this study.

I am most grateful to Mrs Anne Broomfield who aided with DEXA scanning; Mrs Kim Wylie who dissected the femurs in preparation for biomechanical testing; Mr James Liu who assisted with animal care. Thanks also to Mrs Gabrielle Plimmer for her help in biomechanical testing and cell culture experiments. I would like to thank Ms Michelle McGrath, Mrs Shampa De and Mr Corrin Hulls for their assistance in the Bone Laboratory. Many thanks go to all the staff at IFNHH for their assistance in many different ways. It has truly been a wonderful experience.

I sincerely thank Phoebe, Jingjing, Yan, Daisy, Lily, Fang, and my other friends here at New Zealand and China for your warm friendship.

Last but not least, I would like to thank my husband, my friend, Lin Ma, for the love and support throughout. It is such a blessing to have you in my life. I am extremely grateful for my family, who have always been my inspiration and strength.

Table of Contents

Abstract	i
Acknowledgements	iii
Table of Contents	iv
List of figures	vii
List of tables	ix
Abbreviations	x
Introduction	xiii
Chapter 1. Literature Review	1
Section 1. Bone.....	1
1.1 Bone function, structure and composition	1
1.1.1 Skeletal function.....	1
1.1.2 Skeletal structure.....	1
1.1.3 Composition of bone	2
1.2 Bone cells.....	4
1.2.1 The osteoblast.....	4
1.2.2 The osteoclast.....	6
1.2.3 The osteocytes	10
1.3 Bone development and metabolism.....	11
1.3.1 Bone modelling and growth.....	11
1.3.2 Peak bone mass	11
1.3.3 Bone remodelling.....	11
1.4 Regulation of bone metabolism	13
1.4.1 Lifestyle factors.....	13
1.4.2 Effects of hormones	15
1.4.3 Local factors.....	18
Section 2. Mis-regulation of bone metabolism.....	19
1.5 Definition of osteoporosis.....	19
1.6 Pathogenesis of osteoporosis	19
1.6.1 Basic pathogenetic mechanisms.....	19
1.6.2 Risk factors for osteoporosis and osteoporotic fractures	19
1.7 Effects of estrogen imbalance on bone metabolism	21

1.7.1 Effects of estrogen on bone modelling.....	21
1.7.2 Effects of estrogen on bone remodelling	22
Section 3. Dairy and bone health.....	25
1.8 Composition of bovine milk	25
1.8.1 Lipids	25
1.8.2 Proteins.....	28
1.8.3 Other components in bovine milk.....	29
1.9 The relationship between dairy lipids and bone	30
1.9.1 The effect of saturated fatty acids on bone	30
1.9.2 The effect of polyunsaturated fatty acids on bone	37
1.10 The relationship between dairy proteins and bone	47
1.10.1 Epidemiological studies	47
1.10.2 Intervention studies	49
1.10.3 Mechanisms of proteins in bone metabolism.....	50
Section 4. Motivation and objectives	52
1.11 Objectives of the study	52
1.12 Hypothesis	52
Chapter 2. Materials and Methods	53
2.1 Animal study.....	53
2.1.1 Animals	53
2.1.2 Diets	53
2.1.3 Dual Energy X-Ray Absorptiometry (DEXA) Scans	55
2.1.4 Biomechanical Testing.....	56
2.2 Cell culture.....	59
2.2.1 MC3T3-E1 subclone 4 pre-osteoblast like cells	59
2.2.2 Raw 264.7 osteoclastogenesis assay	65
2.3 Statistical analyses	66
Chapter 3. Results	67
3.1 Diet analysis.....	67
3.2 Body weight and feed intake	67
3.2.1 Body weight	67
3.2.2 Feed intake	68
3.3 Body composition of rats.....	70

3.4 Bone density	72
3.4.1 Femurs.....	72
3.4.2 Lumbar spine.....	74
3.4.3 Whole body	76
3.5 Biomechanics.....	78
3.6 Cell culture.....	80
3.6.1 Osteoblasts	80
3.6.2 Osteoclasts	83
Chapter 4. Discussion	86
4.1 Animal study.....	86
4.1.1 Effect of MLF on bone density	86
4.1.2 Biomechanics	91
4.2 Bone cells.....	92
4.2.1 Osteoblasts	92
4.2.2 Osteoclasts	95
4.3 Limitations of the study and future improvements.....	98
4.4 Conclusion	99
Reference list.....	100

List of figures

Figure 1.1	The anatomical features of a long bone.....	2
Figure 1.2	The proposed progress of osteoblast differentiation and proliferation regulated by Wnt/ β -catenin, Cbfa1 (Runx2) and Osx signalling.	5
Figure 1.3	The proposed progress of osteoclastogenesis and the regulatory factors for osteoclast differentiation and activation	7
Figure 1.4	Bone resorption by osteoclasts	9
Figure 1.5	Bone remodelling cycle.....	13
Figure 2.1	Load-Deformation Curve of three-point bending test.	58
Figure 2.2	Arrangement of control and treatments in a 96-well cell culture plate in the osteoblast proliferation assay.....	60
Figure 2.3	Arrangement of control and treatments in a 24-well cell culture plate in the osteoblast differentiation and mineralization assay	62
Figure 2.4	Arrangement of control and treatments in a 24-well cell culture plate in the osteoclastogenesis assay.	66
Figure 3.1	Weekly body weight measurements in Sprague-Dawley rats.....	68
Figure 3.2	Weekly feed intake for Sprague-Dawley rats	69
Figure 3.3	Daily feed intake for Sprague-Dawley rats	69
Figure 3.4	Percentage changes of body composition from baseline after 12 weeks of feeding control or MLF diets.....	72
Figure 3.5	Percentage change for femur bone area, BMC and BMD from baseline after 12 weeks of feeding control or MLF diets	74
Figure 3.6	Percentage change of lumbar spine bone area, BMC and BMD from baseline after 12 weeks of feeding control or MLF diets	76
Figure 3.7	Percentage changes of whole body bone area, BMC and BMD from baseline after 12 weeks of feeding control or MLF diets.....	78

Figure 3.8 Effect of MLF (0-1,000 $\mu\text{g/ml}$) on cell proliferation in MC3T3-E1 sub-clone 4 pre-osteoblasts.....	80
Figure 3.9 Effect of MLF on cell differentiation in MC3T3-E1 sub-clone 4 pre-osteoblasts	81
Figure 3.10 Representative photo of 24-well plate for cell mineralization experiment in MC3T3-E1 sub-clone 4 pre-osteoblasts stained with alizarin red.....	82
Figure 3.11 Effect of MLF on cell mineralization in MC3T3-E1 sub-clone 4 pre-osteoblasts	83
Figure 3.12 Effect of MLF (0.1-100 $\mu\text{g/ml}$) on osteoclastogenesis in RAW 264.7 cells.....	84
Figure 3.13 Effect of MLF (0.1-100 $\mu\text{g/ml}$) on the number of TRAP-positive cells.	85

List of tables

Table 1.1 Hormones involved in bone metabolism	15
Table 1.2 Local factors involved in bone metabolism.	18
Table 2.1 Dietary composition of the control and MLF diets.....	54
Table 2.2 Typical composition of the MLF.	54
Table 3.1 Diet analysis of experimental diets.	67
Table 3.2 Body composition of rats	70
Table 3.3 Changes of DEXA measures of body composition	71
Table 3.4 <i>In vivo</i> femur bone area, bone mineral content (BMC) and bone mineral density (BMD) of rats	73
Table 3.5 Changes of <i>in vivo</i> femur bone area, bone mineral content (BMC) and bone mineral density (BMD) changes after 12 weeks of feeding control or MLF diets.....	73
Table 3.6 <i>In vivo</i> lumbar spine bone area, bone mineral content (BMC) and bone mineral density (BMD) of rats at Week 0 (Baseline) and Week 11.	75
Table 3.7 Changes of <i>in vivo</i> lumbar spine area, bone mineral content (BMC) and bone mineral density (BMD) after 12 weeks of feeding control or MLF diets.....	75
Table 3.8 <i>In vivo</i> whole body bone area, bone mineral content (BMC) and bone mineral density (BMD) of rats at the Week 0 (Baseline) and Week 11. ...	77
Table 3.9 Changes of <i>in vivo</i> whole body bone area, bone mineral content (BMC) and bone mineral density (BMD) after 12 weeks of feeding control or MLF diets.....	77
Table 3.10 Dimensional and biomechanical results from three-point bending tests on the left femurs following 12 weeks of feeding a control or MLF diets. ...	79

Abbreviations

1,25(OH) ₂ D ₃	1,25-dihydroxyvitamin D ₃
AA	Arachidonic acid
ALA	α -linolenic acid
ALP	Alkaline phosphatase
BA	Bone area
BMC	Bone mineral content
BMD	Bone mineral density
BMI	Body mass index
BMP	Bone morphogenic protein
BMU	Basic multicellular unit
BSA	Bovine serum albumin
Cbfa1	Core-binding factor α 1
CLA	Conjugated linoleic acid
COX	Cyclooxygenases
CV	Coefficients of variation
DEXA	Dual energy X-ray absorptiometry
DHA	Docosahexaenoic acid
DMSO	Dimethyl sulfoxide
DPA	Docosapentaenoic acid
DPA	Docosapentaenoic acid
Dpyd	Deoxypyridinoline
EFA	Essential fatty acid
EPA	Eicosapentaenoic acid
ER	Estrogen receptor
ERK	Extracellular regulated kinase
FBS	Fetal bovine serum
FOS	Framingham Osteoporosis Study
GPR	G protein-coupled receptor
HDAC	Histone deacetylase
Hyp	Hydroxyproline
IGF-1	Insulin-like growth factor-1

Ihh	Indian hedgehog
IL	Interleukin
iNOS	inducible nitric oxide synthase
LA	Linoleic acid
LOX	Lipoxygenase
LPS	Lipopolysaccharide
LT	Leukotriene
MAPK	Mitogen-activated protein kinases
MBP	Milk basic protein
M-CSF	Macrophage-colony stimulating factor
MLF	Milk lipid fraction
MSC	Mesenchymal stem cell
MTT	Methyl-thiazolyl tetrazolium
MUFA	Monounsaturated fatty acid
MyD88	Myeloid differentiation factor 88
NF- κ B	Nuclear factor - κ B
NO	Nitric oxide
NTx	N-telopeptides
OPG	Osteoprotegerin
OSX	Osterix
PBS	Phosphate-buffered saline
PGE ₂	Prostaglandin E ₂
p-NPP	p-nitrophenyl phosphate
PPAR _s	Peroxisome proliferator-activated receptors
PTH	Parathyroid hormone
Pyd	Pyridinoline
QC	Quality control
RANK	Receptor activator of nuclear factor - κ B
RANKL	Receptor activator of nuclear factor - κ B ligand
RCT	Randomised controlled trial
SFA	Saturated fatty acid
STAT3	Signal transducer and activator of transcription 3
T ₃	Triiodothyronine

T ₄	Thyroxine
TBS	Tris buffered saline
TFA	Trans-fatty acid
TGF-β	Transforming growth factor-β
TLR4	Toll-like receptor 4
TNF	Tumour necrosis factor
VA	Vaccenic acid
WHO	World Health Organization